HRP20120652T1 - Organski spojevi - Google Patents
Organski spojevi Download PDFInfo
- Publication number
- HRP20120652T1 HRP20120652T1 HRP20120652TT HRP20120652T HRP20120652T1 HR P20120652 T1 HRP20120652 T1 HR P20120652T1 HR P20120652T T HRP20120652T T HR P20120652TT HR P20120652 T HRP20120652 T HR P20120652T HR P20120652 T1 HRP20120652 T1 HR P20120652T1
- Authority
- HR
- Croatia
- Prior art keywords
- staurosporine
- benzoyl
- crystalline form
- solution
- compound
- Prior art date
Links
- 150000002894 organic compounds Chemical class 0.000 title 1
- BMGQWWVMWDBQGC-IIFHNQTCSA-N midostaurin Chemical compound CN([C@H]1[C@H]([C@]2(C)O[C@@H](N3C4=CC=CC=C4C4=C5C(=O)NCC5=C5C6=CC=CC=C6N2C5=C43)C1)OC)C(=O)C1=CC=CC=C1 BMGQWWVMWDBQGC-IIFHNQTCSA-N 0.000 claims abstract 13
- 150000001875 compounds Chemical class 0.000 claims abstract 11
- 238000002441 X-ray diffraction Methods 0.000 claims abstract 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 8
- 239000002904 solvent Substances 0.000 claims 6
- 238000000034 method Methods 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 239000007787 solid Substances 0.000 claims 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims 3
- 239000002244 precipitate Substances 0.000 claims 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- 238000002955 isolation Methods 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- NOGFHTGYPKWWRX-UHFFFAOYSA-N 2,2,6,6-tetramethyloxan-4-one Chemical compound CC1(C)CC(=O)CC(C)(C)O1 NOGFHTGYPKWWRX-UHFFFAOYSA-N 0.000 claims 1
- GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 238000010521 absorption reaction Methods 0.000 claims 1
- 238000000862 absorption spectrum Methods 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000001035 drying Methods 0.000 claims 1
- HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 claims 1
- 239000000047 product Substances 0.000 claims 1
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 claims 1
- CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Extraction Or Liquid Replacement (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62534304P | 2004-11-05 | 2004-11-05 | |
| US64213105P | 2005-01-07 | 2005-01-07 | |
| PCT/EP2005/011789 WO2006048296A1 (fr) | 2004-11-05 | 2005-11-03 | Composes organiques |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20120652T1 true HRP20120652T1 (hr) | 2012-09-30 |
Family
ID=35501294
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20120652TT HRP20120652T1 (hr) | 2004-11-05 | 2012-08-10 | Organski spojevi |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US8198435B2 (fr) |
| EP (3) | EP2955186A1 (fr) |
| JP (4) | JP5057986B2 (fr) |
| KR (3) | KR101265850B1 (fr) |
| CN (2) | CN102627658A (fr) |
| AR (1) | AR052322A1 (fr) |
| AU (2) | AU2005300693B2 (fr) |
| BR (1) | BRPI0517689A (fr) |
| CA (1) | CA2584911C (fr) |
| CY (1) | CY1113059T1 (fr) |
| DK (1) | DK1812448T3 (fr) |
| EC (1) | ECSP12007431A (fr) |
| ES (1) | ES2388142T3 (fr) |
| GT (1) | GT200500311A (fr) |
| HK (2) | HK1108881A1 (fr) |
| HR (1) | HRP20120652T1 (fr) |
| IL (3) | IL182691A (fr) |
| JO (1) | JO2897B1 (fr) |
| MA (1) | MA29033B1 (fr) |
| MX (2) | MX2007005429A (fr) |
| MY (2) | MY154878A (fr) |
| NO (2) | NO338960B1 (fr) |
| NZ (3) | NZ554653A (fr) |
| PE (3) | PE20130377A1 (fr) |
| PL (1) | PL1812448T3 (fr) |
| PT (1) | PT1812448E (fr) |
| RU (2) | RU2394038C2 (fr) |
| SI (1) | SI1812448T1 (fr) |
| TN (1) | TNSN07165A1 (fr) |
| TW (4) | TWI530500B (fr) |
| WO (1) | WO2006048296A1 (fr) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE602007013567D1 (de) | 2006-08-16 | 2011-05-12 | Novartis Ag | Verfahren zur herstellung fester dispersionen von midostaurin |
| EP2327706A1 (fr) * | 2009-11-30 | 2011-06-01 | Novartis AG | Formes polymorphiques III et IV de la N-benzoyl-staurosporine |
| KR20160008267A (ko) | 2014-07-14 | 2016-01-22 | 주식회사 윈스 | 네트워크 기반 영상감시체계에서의 사용자 행위 분석 시스템 |
| EP3592749A1 (fr) * | 2017-03-06 | 2020-01-15 | Teva Pharmaceutical Works Ltd. | Formes à l'état solide de midostaurine |
| WO2019215759A1 (fr) * | 2018-05-09 | 2019-11-14 | Alaparthi Lakshmi Prasad | Procédé amélioré de préparation de midostaurine |
| IT201900004729A1 (it) | 2019-03-29 | 2020-09-29 | Procos Spa | Processo per la preparazione di midostaurina ad elevato grado di purezza |
| US20220242880A1 (en) * | 2019-06-24 | 2022-08-04 | Dr. Reddy?s Laboratories Limited | Process for preparation of midostaurin |
| IT201900014346A1 (it) | 2019-08-08 | 2021-02-08 | Procos Spa | Processo per la preparazione di midostaurina amorfa con un basso contenuto di solvente organico residuo |
| IT202000004291A1 (it) | 2020-03-02 | 2021-09-02 | Indena Spa | Processo per la purificazione di alcaloidi indolo carbazolici |
| CN111393454A (zh) * | 2020-05-07 | 2020-07-10 | 奥锐特药业(天津)有限公司 | 米哚妥林的新晶型及其制备方法 |
| CN115124551B (zh) * | 2021-03-24 | 2024-04-30 | 奥锐特药业(天津)有限公司 | 一种高纯度米哚妥林的制备方法 |
| WO2023205504A1 (fr) * | 2022-04-22 | 2023-10-26 | Rutgers, The State University Of New Jersey | Formulations et méthodes de traitement de l'épidermolyse bulleuse simple et d'affections associées |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5373501A (en) * | 1976-12-11 | 1978-06-30 | Kitasato Inst | Novel antibiotics amm2282 and process for preparing same |
| JPS60185719A (ja) | 1984-03-06 | 1985-09-21 | Ajinomoto Co Inc | 抗腫瘍剤 |
| IL86632A0 (en) * | 1987-06-15 | 1988-11-30 | Ciba Geigy Ag | Derivatives substituted at methyl-amino nitrogen |
| US5093330A (en) | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
| US5073633A (en) * | 1989-03-23 | 1991-12-17 | Bristol-Myers Company | BMY-41950 antitumor antibiotic |
| US5096330A (en) * | 1990-06-21 | 1992-03-17 | M-B-W Inc. | Pitch control mechanism for a surface finishing machine |
| JPH05247055A (ja) * | 1992-03-03 | 1993-09-24 | Meiji Seika Kaisha Ltd | スタウロスポリン誘導体及びそれを含有する抗腫瘍効果増強剤 |
| JPH05247955A (ja) | 1992-03-06 | 1993-09-24 | Taisei Corp | 擁壁の施工方法 |
| EP0575955B1 (fr) | 1992-06-22 | 1999-09-15 | Kyowa Hakko Kogyo Co., Ltd. | Procédé pour la préparation de dérivés de staurosporine |
| JPH10501527A (ja) * | 1994-06-01 | 1998-02-10 | チバ−ガイギー アクチェンゲゼルシャフト | 多重薬剤耐性細胞を抗腫瘍剤に対して感受性にするためのインドロカルバゾール誘導体 |
| RU2191175C2 (ru) | 1995-12-11 | 2002-10-20 | Сефалон, Инкорпорейтед | Конденсированные изоиндолоны в качестве ингибиторов протеинкиназы с |
| CN1367789B (zh) * | 1999-08-30 | 2012-06-06 | 波利弗尔股份公司 | 模板固定的β-发夹环模拟物的合成 |
| CA2439097C (fr) | 2001-03-26 | 2010-10-12 | Novartis Ag | Compositions pharmaceutiques |
| KR100407758B1 (ko) | 2001-08-27 | 2003-12-01 | 씨제이 주식회사 | 스타틴의 제조에 있어서 락톤화 방법 |
| WO2004094645A1 (fr) * | 2003-04-22 | 2004-11-04 | Lonza Ag | Procede de recuperation de staurosporine a partir d'un bouillon de fermentation |
-
2005
- 2005-10-26 JO JO2005162A patent/JO2897B1/en active
- 2005-10-28 GT GT200500311A patent/GT200500311A/es unknown
- 2005-10-28 MY MYPI20091911A patent/MY154878A/en unknown
- 2005-10-28 MY MYPI20055091A patent/MY147404A/en unknown
- 2005-11-03 MX MX2007005429A patent/MX2007005429A/es active IP Right Grant
- 2005-11-03 KR KR1020127022582A patent/KR101265850B1/ko active IP Right Grant
- 2005-11-03 CN CN2012101018747A patent/CN102627658A/zh active Pending
- 2005-11-03 BR BRPI0517689-1A patent/BRPI0517689A/pt not_active IP Right Cessation
- 2005-11-03 NZ NZ554653A patent/NZ554653A/en not_active IP Right Cessation
- 2005-11-03 NZ NZ588025A patent/NZ588025A/en not_active IP Right Cessation
- 2005-11-03 JP JP2007539535A patent/JP5057986B2/ja active Active
- 2005-11-03 KR KR1020127022584A patent/KR101289998B1/ko active IP Right Grant
- 2005-11-03 ES ES05803350T patent/ES2388142T3/es active Active
- 2005-11-03 US US11/718,029 patent/US8198435B2/en active Active
- 2005-11-03 NZ NZ599033A patent/NZ599033A/xx not_active IP Right Cessation
- 2005-11-03 WO PCT/EP2005/011789 patent/WO2006048296A1/fr active Application Filing
- 2005-11-03 CN CN2012104320940A patent/CN102993213A/zh active Pending
- 2005-11-03 KR KR1020077010191A patent/KR101333851B1/ko active IP Right Grant
- 2005-11-03 PT PT05803350T patent/PT1812448E/pt unknown
- 2005-11-03 DK DK05803350.7T patent/DK1812448T3/da active
- 2005-11-03 PL PL05803350T patent/PL1812448T3/pl unknown
- 2005-11-03 CA CA2584911A patent/CA2584911C/fr active Active
- 2005-11-03 EP EP15171908.5A patent/EP2955186A1/fr not_active Withdrawn
- 2005-11-03 MX MX2011007303A patent/MX346525B/es unknown
- 2005-11-03 SI SI200531555T patent/SI1812448T1/sl unknown
- 2005-11-03 AU AU2005300693A patent/AU2005300693B2/en active Active
- 2005-11-03 RU RU2007120695/04A patent/RU2394038C2/ru active
- 2005-11-03 EP EP05803350A patent/EP1812448B1/fr active Active
- 2005-11-03 EP EP10173464.8A patent/EP2272850B1/fr active Active
- 2005-11-04 TW TW101122880A patent/TWI530500B/zh not_active IP Right Cessation
- 2005-11-04 TW TW101122882A patent/TWI455941B/zh not_active IP Right Cessation
- 2005-11-04 TW TW094138677A patent/TWI433852B/zh not_active IP Right Cessation
- 2005-11-04 PE PE2012002519A patent/PE20130377A1/es not_active Application Discontinuation
- 2005-11-04 PE PE2005001297A patent/PE20060947A1/es not_active Application Discontinuation
- 2005-11-04 PE PE2009000199A patent/PE20090433A1/es not_active Application Discontinuation
- 2005-11-04 AR ARP050104637A patent/AR052322A1/es not_active Application Discontinuation
- 2005-11-04 TW TW103130302A patent/TWI530501B/zh not_active IP Right Cessation
-
2007
- 2007-04-19 IL IL182691A patent/IL182691A/en active IP Right Grant
- 2007-05-02 NO NO20072290A patent/NO338960B1/no unknown
- 2007-05-04 TN TNP2007000165A patent/TNSN07165A1/fr unknown
- 2007-05-22 MA MA29924A patent/MA29033B1/fr unknown
- 2007-12-19 HK HK07113889.0A patent/HK1108881A1/xx unknown
- 2007-12-19 HK HK15112508.3A patent/HK1211587A1/xx unknown
-
2009
- 2009-10-13 RU RU2009137788/04A patent/RU2467012C2/ru active
- 2009-12-07 AU AU2009245817A patent/AU2009245817B2/en active Active
-
2010
- 2010-08-19 IL IL207702A patent/IL207702A/en active IP Right Grant
-
2012
- 2012-01-16 IL IL217571A patent/IL217571A/en active IP Right Grant
- 2012-03-12 EC ECSP12007431 patent/ECSP12007431A/es unknown
- 2012-05-11 JP JP2012109447A patent/JP5701246B2/ja active Active
- 2012-05-15 US US13/472,130 patent/US8710216B2/en active Active
- 2012-08-10 HR HRP20120652TT patent/HRP20120652T1/hr unknown
- 2012-08-21 CY CY20121100747T patent/CY1113059T1/el unknown
-
2015
- 2015-01-09 JP JP2015003634A patent/JP2015063569A/ja not_active Withdrawn
-
2016
- 2016-07-12 NO NO20161152A patent/NO340404B1/no unknown
-
2017
- 2017-01-13 JP JP2017004320A patent/JP2017061578A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20120652T1 (hr) | Organski spojevi | |
| Mathew et al. | Novel pyridopyrazine and pyrimidothiazine derivatives as FtsZ inhibitors | |
| Li et al. | Synthesis and evaluation of a novel series of heterocyclic oleanolic acid derivatives with anti-osteoclast formation activity | |
| CZ303702B6 (cs) | Minocyklinové slouceniny | |
| CN101362718B (zh) | 4-(4-苯甲酰氨基苯氧基)-2-(甲基氨甲酰基)吡啶衍生物及其制备方法和用途 | |
| HRP20160246T4 (hr) | Dimaleat od aminokrotonilskog spoja i postupak njegove proizvodnje | |
| JP2004502750A (ja) | ７、８および９−置換テトラサイクリン化合物 | |
| CA2700844A1 (fr) | Compositions d'imatinib stables | |
| US20090275585A1 (en) | Novel Compounds and Therapeutic Use Thereof for Protein Kinase Inhibition | |
| CN103607888A (zh) | 取代的甲基甲酰基试剂以及使用所述试剂改进化合物的物理化学性质和/或药代动力学性质的方法 | |
| JP4654187B2 (ja) | テクトリゲニンのイソフラボン誘導体、その調製、および有効成分としてこれを含む抗ウィルス剤 | |
| US20150072987A1 (en) | Novel compounds and therapeutic use thereof for protein kinase inhibition | |
| CN104109115A (zh) | 一种含氮杂环链接的苯丙酸类化合物、其药物组合物、制备方法和用途 | |
| WO2022107745A1 (fr) | Agent thérapeutique ou agent prophylactique contre la covid-19 | |
| WO2004005309A3 (fr) | Substances anti-inflammatoires non steroidiennes, compositions et procedes d'utilisation de celles-ci | |
| JPH06501944A (ja) | Ｎ−（２−アルキル−３−メルカプトグルタリル）−アミノ−ジアザシクロアルカノン誘導体およびそれらのコラゲナーゼ抑制薬としての使用 | |
| CN113336735B (zh) | 一种尿石素类化合物、制备方法、药物组合物及用途 | |
| CN108299255B (zh) | 组蛋白去乙酰化酶8选择性抑制剂及其制备方法和应用 | |
| ES2544327T3 (es) | Sales de amina de un derivado de carboestirilo útiles para el tratamiento de, entre otras, una úlcera gástrica | |
| CN102452986B (zh) | N-甲酰羟胺类化合物及其制备方法和用途 | |
| HRP20050831A2 (en) | Novel oxazole derivatives, their manufacture and use as pharmaceutical agents | |
| CA2105683C (fr) | Acides n-¬(4,5-dihydroxy-et 4,5,8-trihydroxy-9,10-dihydro-9, 10-dioxo-2-anthracene-yl)carbonyl|amines utiles pour les therapies d'affectations osteoarticulaires | |
| US20030120073A1 (en) | Alpha-ketocarboxylic acid based inhibitors of phosphoryl tyrosine phosphatases | |
| CN102443005A (zh) | 查尔酮的螺杂环类化合物及其用途 | |
| HRP20120926T1 (hr) | Stereoselektivni postupak i kristalni oblici kamptotecina |